

Washington State Pharmacy and Therapeutics Committee & Drug Utilization Review Board
Meeting by Zoom Webinar
Wednesday, April 16, 2025, 9 a.m. to 4 p.m.

Agenda		
Time	Topic	Presenter
9 a.m.	Welcome & Introductions Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Peter Barkett, Committee Chair
	P&T/DUR Overview	Donna Sullivan, HCA
	Drug Utilization Presentation	Ryan Taketomo, HCA
	Break (10min)	All
	Apple Health Policy: 21.40.24 Oncology Agents : Antiandrogens- Oral <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Marissa Tabile, HCA
	Apple Health Policy: 30.10.00 Endocrine and Metabolic Agents : Growth Hormones <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Luke Dearden, HCA
	Apple Health Policy: 66.27.00.AB Cytokine and CAM Antagonists : IL-4/IL-13 Inhibitors <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Marissa Tabile, HCA
	Apple Health Policy: 66.27.00.AH Cytokine and CAM Antagonists : JAK Inhibitors <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Ryan Taketomo, HCA
	Apple Health Policy: 90.78.40 Topical Immunosuppressives - Calcineurin Inhibitors <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Luke Dearden, HCA
	Lunch (30 min)	All
	Anticonvulsants <ul style="list-style-type: none"> • AMPA Glutamate Receptor Antagonists • Benzodiazepines - Rescue Agents • Misc 	Nina Huynh, Prime

** Stakeholders will be allowed 3 minutes for comments.*
Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions
 please call Nonye Connor at 360-725-2044.

	<ul style="list-style-type: none"> • Succinimides <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	
	<p>Antidementia Agents</p> <ul style="list-style-type: none"> • - • Anti-Amyloid Antibodies <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	<p>Asthma and COPD Agents</p> <ul style="list-style-type: none"> • Anticholinergics • Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations • Long Acting Muscarinic Agents • Phosphodiesterase 4 Inhibitors • Monoclonal Antibodies <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	<p>Atopic Dermatitis Agents</p> <ul style="list-style-type: none"> • Janus Kinase (JAK) Inhibitors – Oral • Janus Kinase (JAK) Inhibitors – Topical • Monoclonal Antibodies • Phosphodiesterase 4 Inhibitors - Topical <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	Break (10min)	All
	<p>Cytokine And Cam Antagonists :</p> <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	<p>Hematopoietic Agents</p> <ul style="list-style-type: none"> • Erythroid Maturation Agents • Erythropoiesis-Stimulating Agents (ESAS) • Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors • Granulocyte Colony-Stimulating Factors (G-CSF) <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	<p>Neuromuscular Agents</p> <ul style="list-style-type: none"> • Muscular Dystrophy Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	<p>Oncology Agents</p> <ul style="list-style-type: none"> • Isocitrate Dehydrogenase-1 (IDH1) Inhibitors – Oral • Autologous Cellular Immunotherapy (CAR-T) <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	<p>Asthma and COPD Agents</p> <ul style="list-style-type: none"> • Inhaled Corticosteroid Combinations • Inhaled Corticosteroids <p>Atopic Dermatitis Agents</p> <ul style="list-style-type: none"> • Immunosuppressive Agents - Topical <p>Corticosteroids</p>	Marissa Tabile, HCA Nina Huynh, Prime

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	<ul style="list-style-type: none"> • Glucocorticosteroids - Oral <p>Hematopoietic Agents</p> <ul style="list-style-type: none"> • Gaucher Disease • Sickle Cell Anemia • Sickle Cell Anemia - Selectin Blockers <p>Oncology Agents</p> <ul style="list-style-type: none"> • Alkylating Agents – Oral • Antiadrenals – Oral • Antiestrogens – Oral • Antimetabolites – Oral • Antineoplastic Estrogens – Oral • Antineoplastics Misc – Oral • BCL-2 Inhibitors – Oral • Gene Therapies • Histone Deacetylase Inhibitors – Oral • Imidazotetrazines – Oral • Immune Modulators • Isocitrate Dehydrogenase-2 (IDH2) Inhibitors – Oral • Janus Associated Kinase (JAK) Inhibitors – Oral • Mitotic Inhibitors – Oral • Nitrogen Mustards – Oral • Nitrosoureas – Oral • Phosphatidylinositol 3-Kinase (PI3K) Inhibitors – Oral • Proteasome Inhibitors – Oral • Selective Retinoid X Receptor Agonists – Oral • XPO1 Inhibitors - Oral <p>All classes in this section:</p> <ul style="list-style-type: none"> • Stakeholder input* • Motion 	
4:00 p.m.	Drug Utilization Review (DUR) Board Adjourns	Peter Barkett, Committee Chair

For all Apple Health (Medicaid) questions:

1. Go to [HCA Support](#).
2. Click **Public**. You will need a SecureAccess Washington (SAW) account. ([View instructions for accessing SAW.](#))
3. Once you have logged into SAW, you will see the HCA Support portal.
4. Click **Make a Request**.
5. Click the **Apple Health Pharmacy** tile. This will take you to the online form.

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.